A5000489992- Pancreatic and Hepatic Oncology Research
- Gallbladder and Bile Duct Disorders
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- Pancreatitis Pathology and Treatment
- Pediatric Hepatobiliary Diseases and Treatments
- Esophageal and GI Pathology
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Renal cell carcinoma treatment
- Cancer Treatment and Pharmacology
- Biliary and Gastrointestinal Fistulas
- Cancer Diagnosis and Treatment
- Nutrition and Health in Aging
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Gastrointestinal disorders and treatments
- Gastric Cancer Management and Outcomes
- Scoliosis diagnosis and treatment
- Medical Imaging and Analysis
- Hepatocellular Carcinoma Treatment and Prognosis
- Epigenetics and DNA Methylation
- Spinal Fractures and Fixation Techniques
- Colorectal Cancer Treatments and Studies
- Autonomous Vehicle Technology and Safety
- Video Surveillance and Tracking Methods
Tokyo City University
2021-2024
Japanese Foundation For Cancer Research
2014-2023
Cancer Institute (WIA)
2016-2023
The Cancer Institute Hospital
2010-2021
Tokyo Medical University
2013
Chiba University
1968-2008
Fujita Health University
1998
Kurume University
1982-1989
Abstract Background There is no established second-line treatment after failure of gemcitabine plus nab-paclitaxel (GnP) therapy for metastatic pancreatic cancer (MPC). The purpose this study was to evaluate the efficacy and tolerability modified FOLFIRINOX (mFFX) as a MPC investigate prognostic factors survival. Methods From 2015 2019, we retrospectively reviewed medical records consecutive patients receiving mFFX GnP therapy. Patients were treated every 2 weeks with (intravenous...
Liver oligometastatic pancreatic cancer (PC) may have favorable outcomes. This study aims to evaluate outcomes and factors associated with overall survival (OS) of these patients.We retrospectively investigated consecutive PC patients liver metastasis treated at our institution between 2013 2020. Clinical characteristics were compared analyzed according the extent metastasis. Cox proportional hazards model was used identify prognostic for OS.A total 417 included (multi-organ...
It has been suggested that a heparin-binding growth factor, midkine (MK), plays an important role in carcinogenesis because of its frequent overexpression various malignant tumours. To clarify whether or not MK contributes to the early stage carcinogenesis, we examined status mRNA 20 adenomas with moderate- and severe-grade dysplasia, 28 carcinomas corresponding normal tissues, by means Northern blotting. The expression level was significantly more elevated than tissues (P < 0.001, unpaired...
Endoscopic nasobiliary drainage (ENBD) is often recommended in preoperative biliary (PBD) for hilar malignant obstruction (MBO), but endoscopic stent (EBS) also used the clinical practice. We conducted this large-scale multicenter study to compare ENBD and EBS setting.A total of 374 cases undergoing PBD including 281 76 MBO 29 centers were retrospectively studied.Extrahepatic cholangiocarcinoma (ECC) accounted 69.8% Bismuth-Corlette classification was III or more 58.8% population....
FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, oxaliplatin) and gemcitabine plus nab-paclitaxel therapy have recently been introduced for the treatment of metastatic pancreatic cancer. Herein, overall outcomes cancer after introduction were evaluated, in daily practice.Metastatic patients (n=321) who started systemic chemotherapy between January 2011 December 2016 included divided into two groups: group A (2011-2013) B (2014-2016). Treatment evaluated retrospectively.Patient...
BACKGROUND. Pancreatic ductal adenocarcinoma (PDAC) is highly lethal, partly because of challenges in early diagnosis. However, the prognosis for earlier stages (carcinoma situ or category T1a invasive carcinoma) relatively favorable. OBJECTIVE. The purpose this study was to investigate findings an diagnosis PDAC on CT examinations performed at least 1 year before clinical stage I PDAC. METHODS. This retrospective included 103 patients with and a examination that detected PDAC, as well...
Stenting against recurrent biliary obstruction (RBO) after placement of covered metal stent (CMS) for distal malignant (MBO) is still challenging. This study investigated the feasibility a novel laser-cut fully CMS with anti-reflux valve in patients MBO refractory to conventional CMS.Patients who underwent Duckbill-type (DMS) between June 2019 and May 2020 were included. Early complications, causes RBO including non-occlusion cholangitis, time (TRBO) evaluated. TRBO DMS was also compared...
Helicobacter pylori infection is a well-established risk factor for gastric cancer and has been linked to other gastrointestinal diseases, including pancreatic biliary tract cancers; however, the relevance of enterohepatic non-H. helicobacters pathophysiology these diseases remains unclear.We estimated prevalence two (Helicobacter hepaticus bilis) in framework hospital-based case-control study involving 121 patients with cancer, or diseases. Bile blood samples were collected from undergoing...
Objective Anamorelin, a novel selective ghrelin receptor agonist, was approved in Japan for the treatment of cachexia pancreatic cancer (PC), albeit with limited evidence. This study evaluated efficacy and safety anamorelin PC examined impact extent weight loss on anamorelin. Methods We retrospectively investigated consecutive patients who received at our institution between June 2021 January 2022. Patients were divided into two groups: moderate-weight-loss group (5-10%) severe-weight-loss...
This study was conducted to assess changes in tumor vascularity using contrast-enhanced ultrasonography patients with pancreatic carcinoma under systemic chemotherapy and examine the correlation among vascular change, clinicopathologic factors, outcome.Forty-one consecutive histopathologically confirmed who had distant metastases were recruited. Contrast-enhanced performed before after 1 2 cycles of treatment.The signals from continuously recorded,and highest signal intensity selected...
To clarify the effectiveness and safety of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) for diagnosis pancreatic cancer (PC).Patients who were diagnosed with unresectable, locally advanced or metastatic PC between February 2006 September 2011 selected this retrospective study. FNA biopsy tumors had been performed percutaneously under extracorporeal ultrasound guidance until October 2009; then, beginning in November 2009, EUS-FNA has performed. We reviewed complete medical...
Abstract We genotyped 2 SNPs (rs3790844 T/C and rs3790843 G/A) in the NR5A2 gene that were identified a genome-wide association study (GWAS) of pancreatic cancer populations mainly European ancestry we examined their associations with risk case-control 360 patients 400 control subjects Japan. Unconditional logistic regression models used to estimate odds ratios (ORs) 95% confidence intervals (CIs). The linkage disequilibrium (r = 0.80). For rs3790843, multivariable-adjusted OR was 0.75 (95%...
Abstract Background/purpose It has been suggested that pancreatic ductal adenocarcinoma (PDAC) and intraepithelial neoplasia (PanIN) are closely related, but several reports indicate PanIN lesions can also be found in normal pancreata (normal PanINs). We examined differences mucin expression between PanINs PDACs (PDAC Methods 54 autopsied eight for lesions; graded the specimens as PanIN‐1A (non‐papillary hyperplasia), PanIN‐1B (papillary PanIN‐2 (atypical hyperplasia) or PanIN‐3 (carcinoma...
Abstract Background and study aims Self-expandable metallic stents (SEMS) are now widely used even for patients with borderline resectable (BR) pancreatic cancer (PC), as neoadjuvant therapy has become common. Therefore, we conducted this to evaluate safety of SEMS placement in the population including BR PC explore risk factors recurrent biliary obstruction (RBO), pancreatitis, cholecystitis. Patients methods We retrospectively investigated consecutive who received initial between January...
Abstract Objective With the introduction of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel therapy for unresectable pancreatic cancer, erlotinib is now occasionally used as late-line therapy. This study investigates outcomes treatment with cancer. Methods We retrospectively analysed consecutive patients cancer treated third or later-line chemotherapy between March 2014 December 2020 in our hospital. Results A total 56 were included (third line/fourth later line = 42/14). All...
Outcomes and prognostic factors of second-line gemcitabine plus nab-paclitaxel (GnP) after modified FOLFIRINOX (mFFX) for unresectable pancreatic cancer were unclear. We retrospectively analyzed consecutive patients with treated GnP first-line mFFX treatment between March 2015 2022 at our hospital. A total 103 included. Median overall survival (OS) from the start treatments was 14.9 months 7.2 months, respectively. progression-free (PFS) 3.6 months. Performance status, Glasgow score,...
Background Elpamotide is an HLA-A*24:02-restricted epitope peptide of vascular endothelial growth factor receptor 2 (VEGFR-2) and induces cytotoxic T lymphocytes (CTLs) against VEGFR-2/KDR. Given the high expression VEGFR-2 in biliary tract cancer, combination chemoimmunotherapy with elpamotide gemcitabine holds promise as a new therapy. Patients Methods unresectable advanced or recurrent cancer were included this single-arm phase II trial, primary endpoint overall survival. Survival...
Abstract Background Although the efficacy of neoadjuvant chemotherapy with gemcitabine plus S-1 (NAC GS) has recently been reported in resectable pancreatic cancer, severe adverse events were frequently observed. Sarcopenia to be associated reduced antitumor response and toxicity several malignancies. The aim this study is evaluate impact body composition on short-term outcomes NAC GS cancer patients. Methods Clinicopathological data consecutive patients treated at our institution from...